By IANS
Hyderabad : Suven Life Sciences has submitted an application with the Drug Controller General of India for permission to undertake phase-1 clinical trials of its new drug Suvn-502 for treatment of cognitive disorders such as Alzheimer's and schizophrenia.
"Treatment for Alzheimer's disease and Schizophrenia is an unmet medical need and Suven's primary focus is to discover drugs that address significant unmet medical needs," said a statement by the firm.
Suven is a Hyderabad-based life sciences company, which is involved in contract research and manufacturing services, drug discovery and development support services and collaborative research partner with global pharma majors.
Suven's research focuses on developing treatments for Central Nervous System (CNS) disorders through novel mechanisms using small-molecule medicinal chemistry approaches.